Mangafodipir (trisodium)

Mangafodipir (trisodium)

• CAS Number: 140678-14-4
• UNSPSC Description: Mangafodipir trisodium (MnDPDP), hepatocellular-specific contrast agent, is an efficacious inhibitor of CIPN (chemotherapy-induced peripheral neuropath) and other conditions caused by cellular oxidative stress. Mangafodipir trisodium shows no negative interference with the tumoricidal activity of chemotherapy[1][2].
• Target Antigen: Apoptosis
• Type: Reference compound
• Related Pathways: Apoptosis
• Field of Research: Neurological Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Mangafodipir-trisodium.html
• Purity: 99.82
• Solubility: H2O : 33.33 mg/mL (ultrasonic)
• Smiles: O=C1[O-][Mn+2]([N]2(C3)CC4=C5COP(O)(O)=O)([O-]C6=C(N=C7)C)([O-]C4=C(N=C5)C)([O-]C3=O)[N](CC6=C7COP([O-])(O)=O)(CC2)C1.[Na+].[Na+].[Na+]
• Molecular Weight: 757.32
• References & Citations: [1]Karlsson JOG, et al. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Transl Oncol. 2017 Aug;10(4):641-649. |[2]Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol Suppl. 1998;415:1-31.|[3]Qin Y, et al. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice. Reprod Biol Endocrinol. 2018 Oct 27;16(1):106.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched